Chinese Laws for Pharmaceutical Patent Protection Collected in New Report Published at MarketPublishers.com

01 Mar 2012 • by Natalie Aster

LONDON – By 2015, China is expected to become the second largest drug market in the world with an annual growth rate of over 25% in next three years, attracting more and more overseas pharmaceutical manufacturers and producers from abroad. However, the Chinese social environment for the protection of intellectual property right is complex. To penetrate such a complex and lucrative market, most overseas and multinational pharmaceutical firms should know how not to let their imported drugs and China-made pharmaceuticals be imitated or copied as well as their intellectual property be infringed and benefit be violated. Though, lack of knowledge of the Chinese intellectual property right system and legislation institution, the cultural difference between China and Western countries as well as the language barriers are among the major challenges faced by these companies.

New report “China’s Guidebook for Pharmaceutical Patent Protection” prepared by Access China Management Consulting (Access China) provides a comprehensive and thorough knowledge of the Chinese patent system relating to pharmaceuticals, the detailed administrative, civil and criminal judicial pathways for protections of patent right, and the design for composition of optimized protection strategies.

Guidebook Highlights:

organization structure of patent authorities and judicial system;

comprehensive and thorough knowledge of the Chinese patent system and the relevant laws and administrative regulations relating to pharmaceuticals;

English versions of latest patent law of the People’s Republic of China (PRC) and the rules for the implementation of the patent law of the PRC to facilitate overseas pharmaceutical manufacturers and multinational pharmaceutical companies to understand the Chinese patent law and regulations.